CAR immune cells: design principles, resistance and the next generation
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …
promising immunotherapeutic approach to fight cancers. This approach consists of …
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …
tremendous progress with five CAR T therapies approved by the US Food and Drug …
CAR T cells in solid tumors: challenges and opportunities
F Marofi, R Motavalli, VA Safonov… - Stem cell research & …, 2021 - Springer
Background CARs are simulated receptors containing an extracellular single-chain variable
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
Navigating CAR-T cells through the solid-tumour microenvironment
AJ Hou, LC Chen, YY Chen - Nature reviews Drug discovery, 2021 - nature.com
The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
[HTML][HTML] Engineering CAR-T cells for next-generation cancer therapy
T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …
shown remarkable success in treating patients with hematologic malignancies and …
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020 - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
'Off-the-shelf'allogeneic CAR T cells: development and challenges
Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …
Tumor microenvironment signaling and therapeutics in cancer progression
Tumor development and metastasis are facilitated by the complex interactions between
cancer cells and their microenvironment, which comprises stromal cells and extracellular …
cancer cells and their microenvironment, which comprises stromal cells and extracellular …
Treg cell-based therapies: challenges and perspectives
Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …